Erlotinib plus bevacizumab combination studies

Erlotinib plus bevacizumab is a clinical guideline-recommended first-line treatment option for EGFR Mut+ NSCLC.1


Bevacizumab is an anti-VEGF monoclonal antibody that inhibits tumour growth by inhibiting new and recurrent tumour vessel growth.2


Bevacizumab also reduces tumour size by regressing existing tumour vasculature.2-4

Please click below for more information on the key clinical trials that demonstrate
erlotinib plus bevacizumab’s favourable efficacy and safety profile in the first-line treatment of EGFR Mut+ NSCLC.

Please note; in some countries the combination of erlotinib plus bevacizumab may not be registered or reimbursed